Clinical Trials Logo

Clinical Trial Summary

Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji. There is a dedicated LF eradication program supported by the World Health Organization (WHO), however scabies and STH are currently managed on an individual level with symptomatic treatment as required.

In an attempt to reduce the prevalence of LF globally, research is being undertaken into alternative, more effective treatment options. A recent study in Papua New Guinea demonstrated a new triple drug therapy (ivermectin, diethylcarbamazine and albendazole) is superior to the currently recommended two drug therapy (diethylcarbamazine and albendazole) used by WHO LF programs in the Pacific. However, adverse events were more frequent. Despite no serious adverse events being observed, it is necessary to conduct further studies to review the safety of this new triple therapy before it can be endorsed as an effective mass drug administration (MDA) regimen for LF in endemic countries. Fiji's burden of LF, that has been recalcitrant to previous MDA with diethylcarbamazine and albendazole, make it an ideal site to obtain further efficacy and safety data of the triple therapy.

Ivermectin given to communities as MDA has been proven to be effective in reducing the community prevalence of scabies. What is not known is the effects of one dose versus two doses of ivermectin as MDA. This question will be reviewed within the design of the community randomized study. The prevalence of impetigo in a community is linked to scabies and this will also be reviewed. Ivermectin and albendazole are both effective individually against STH. The effectiveness of this combination of treatment as MDA in Fiji for STH has not been studied. The effectiveness for the individual in the short-term and the community in the longer-term will be reviewed.

In addition, the acceptability and feasibility of the new therapy in communities at risk of these three diseases will be reviewed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03177993
Study type Interventional
Source Washington University School of Medicine
Contact
Status Completed
Phase N/A
Start date July 13, 2017
Completion date November 19, 2018

See also
  Status Clinical Trial Phase
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Active, not recruiting NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT01153828 - EU PV for Retapamulin-Prescribing N/A
Terminated NCT00986856 - Fucidin® Cream in the Treatment of Impetigo Phase 4
Completed NCT01397461 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Recruiting NCT02090764 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Completed NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Phase 4
Not yet recruiting NCT01611909 - Citriodiol® and Impetigo Phase 2/Phase 3
Completed NCT03429595 - Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo Phase 2
Completed NCT00626795 - Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Phase 2
Completed NCT00758862 - The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Phase 2
Recruiting NCT01943136 - The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Phase 1
Completed NCT01670032 - Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Phase 2/Phase 3
Completed NCT01171326 - Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Phase 2
Completed NCT01367314 - Safety and Efficacy of Topical NVC-422 Gel in Impetigo Phase 2
Completed NCT01126268 - Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Phase 4
Completed NCT00852540 - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Phase 3
Completed NCT00133848 - Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment Phase 3